Eli Lilly and Company

• LLY Stock Price 24h change: -0.80%. From 1087.38 USD to 1078.67 USD.
• From a technical perspective, LLY maintains a "bullish long-term trend" with its 50-day moving average ($1055.5) comfortably above the 200-day average ($867.8); however, short-term momentum is neutral-to-bearish as the RSI sits at 39.9 and the MACD remains below its signal line, suggesting price consolidation or minor pullbacks following its recent peak.
• The FDA granted Breakthrough Therapy designation to Eli Lilly’s drug sofetabart mipitecan for platinum-resistant ovarian cancer, a move expected to accelerate its development and review process.
• Eli Lilly announced a major co-innovation alliance with NVIDIA and Illumina to leverage AI supercomputing for drug discovery and biologics design, involving potential billion-dollar investments in digital R&D.
• Clinical trial updates for Retatrutide showed potential symptomatic relief for knee osteoarthritis tied to weight loss, while a separate UK real-world study was launched to track Tirzepatide’s impact on obesity management.
• The FDA and EMA established ten guiding principles for the safe and ethical use of AI across the biopharmaceutical lifecycle, signaling a standardized regulatory shift toward AI-driven drug development.
• Big Pharma companies, including Pfizer and Novo Nordisk, significantly increased licensing deals with Chinese biotechs for next-generation GLP-1 candidates to diversify obesity treatment pipelines.

• LLY Stock Price 24h change: +3.63%. From 1,041.29 USD to 1,079.13 USD. The jump was fueled by strong clinical trial results for retatrutide in treating obesity-related knee osteoarthritis and a significant FDA Breakthrough Therapy designation for its ovarian cancer drug, sofetabart.
• From a technical perspective, the stock is showing "resilient bullish recovery": LLY recently bounced off its 50-day moving average ($1,053.86) with high trading volume. While the 14-day RSI (45.4) and MACD suggest a neutral-to-slight bearish bias in the short term, the long-term trend remains firmly intact as the price stays above the 200-day moving average ($875.14).
• Eli Lilly received FDA Breakthrough Therapy designation for sofetabart mipitecan, an oncology candidate for platinum-resistant ovarian cancer, accelerating its potential path to market.
• Phase 2 trial results for retatrutide showed it significantly reduced body weight and improved symptoms in patients with knee osteoarthritis and obesity, potentially expanding its GLP-1 franchise indications.
• The company officially confirmed its Q4 2025 earnings release date for February 4, 2026, with analysts expecting EPS of approximately $6.42 on the back of sustained Mounjaro and Zepbound demand.
• Global pharmaceutical companies are reportedly increasing U.S. manufacturing and stockpiling inventory to mitigate potential supply chain disruptions from looming tariff threats and trade policy shifts.
• A new bipartisan deal in Congress aims to boost HHS spending and crack down on drug-industry middlemen, which could impact the pricing and rebate structures of high-cost weight-loss and diabetes medications.